Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 63.55% is in line with its 5-year average of 60.94%, near the high end of its 5-year range (7.60%–84.41%).
2.52% above its 12-month average of 61.99%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 70.35%.
GROSS MARGIN
63.55%
GROSS MARGIN AVG TTM
61.99%
GROSS MARGIN AVG 3Y
56.28%
GROSS MARGIN AVG 5Y
60.94%
GROSS MARGIN AVG 10Y
57.49%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.52%
CURRENT VS 3Y AVG
+12.91%
CURRENT VS 5Y AVG
+4.28%
CURRENT VS 10Y AVG
+10.54%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
+36.64%
vs the sector median at left
Coherus Oncology, Inc.
Market Cap
$169.95M
Gross Margin
63.55%
TTM Avg
61.99%
3Y Avg
56.28%
5Y Avg
60.94%
Market Cap
$171.61M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$173.34M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$177.29M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
Market Cap
$178.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$158.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
1.51%
Market Cap
$183.71M
Gross Margin
62.24%
TTM Avg
61.05%
3Y Avg
61.66%
5Y Avg
60.51%
Market Cap
$155.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $169.95M | 63.55% | 61.99% | 56.28% | 60.94% |
| Compass Therapeutics, Inc. (CMPX)vs › | $171.61M | 0.00% | 50.00% | 25.00% | 16.67% |
| Precision BioSciences, Inc. (DTIL)vs › | $173.34M | 100.00% | 100.00% | 100.00% | 100.00% |
| Cue Biopharma, Inc. (CUE)vs › | $177.29M | 99.69% | 100.00% | -73.48% | -190.92% |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Inogen, Inc. (INGN)vs › | $161.12M | 48.89% | 46.84% | 43.63% | 44.77% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $158.78M | 0.00% | 0.00% | 0.00% | 1.51% |
| Journey Medical Corporation (DERM)vs › | $183.71M | 62.24% | 61.05% | 61.66% | 60.51% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.04M | 0.00% | 0.00% | 0.00% | -29.98% |
| Anavex Life Sciences Corp. (AVXL)vs › | $155.69M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
63.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 70.35% |
| 2026-03-31 | 61.86% |
| 2025-12-31 | 61.24% |
| 2025-09-30 | 59.49% |
| 2025-06-30 | 56.98% |
| 2025-03-31 | 51.32% |
| 2024-12-31 | 37.47% |
| 2024-09-30 | 70.69% |
| 2024-06-30 | 54.52% |
| 2024-03-31 | 37.65% |
| 2023-12-31 | 7.60% |
| 2023-09-30 | 56.14% |
| 2023-06-30 | 57.68% |
| 2023-03-31 | 47.98% |
| 2022-12-31 | 68.68% |
| 2022-09-30 | 22.43% |
| 2022-06-30 | 81.25% |
| 2022-03-31 | 84.41% |
| 2021-12-31 | 83.50% |
| 2021-09-30 | 74.21% |
| 2021-06-30 | 80.95% |
| 2021-03-31 | 90.95% |
| 2020-12-31 | 89.43% |
| 2020-09-30 | 92.07% |
| 2020-06-30 | 92.53% |
| 2020-03-31 | 94.10% |
| 2019-12-31 | 93.70% |
| 2019-09-30 | 94.23% |
| 2019-06-30 | 99.28% |
| 2019-03-31 | 94.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | -2279.93% |
| 2017-03-31 | -33300.62% |
| 2016-12-31 | -6891.71% |
| 2016-09-30 | 60.34% |
| 2016-06-30 | -365.91% |
| 2016-03-31 | -428.47% |
| 2015-12-31 | -400.60% |
| 2015-09-30 | -851.83% |
| 2015-06-30 | -729.36% |
| 2015-03-31 | -527.66% |
| 2014-12-31 | -313.78% |
| 2014-09-30 | -15.23% |
| 2014-06-30 | -281.17% |
| 2014-03-31 | -287.54% |
| 2013-12-31 | -648.54% |
| 2013-09-30 | -875.10% |
| 2013-06-30 | -1570.02% |
| 2013-03-31 | -1610.67% |
